What is Erste Group Bank’s Forecast for NVO FY2026 Earnings?

Posted by Geri Gentry on Oct 28th, 2026

Novo Nordisk A/S (NYSE:NVO – Free Report) – Analysts at Erste Group Bank increased their FY2026 earnings per share estimates for shares of Novo Nordisk A/S in a note issued to investors on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $3.30 per share for the year, up from their prior forecast of $3.29. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.42 per share. Erste Group Bank also issued estimates for Novo Nordisk A/S’s FY2027 earnings at $3.27 EPS.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The firm had revenue of $11.98 billion for the quarter.

A number of other brokerages also recently issued reports on NVO. DZ Bank reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Thursday, August 6th. Jefferies Financial Group restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Berenberg Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Friday, October 9th. Finally, UBS Group reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Five investment analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $59.44.

Check Out Our Latest Analysis on NVO

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $38.70 on Wednesday. The stock’s 50-day simple moving average is $41.65 and its two-hundred day simple moving average is $44.63. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a dividend of $0.5786 per share. The ex-dividend date was Monday, August 17th. This is a decrease from Novo Nordisk A/S’s previous dividend of $1.2751. This represents a yield of 258.0%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Novo Nordisk A/S by 2,414.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock valued at $14,280,000 after purchasing an additional 286,034 shares during the period. Trust Co. of Vermont acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth $1,250,000. Pine Valley Investments Ltd Liability Co acquired a new position in Novo Nordisk A/S during the 2nd quarter valued at about $2,324,000. Myriad Asset Management Advisors LLC purchased a new stake in Novo Nordisk A/S in the second quarter valued at about $1,846,000. Finally, The Manufacturers Life Insurance Company raised its stake in Novo Nordisk A/S by 22.6% in the second quarter. The Manufacturers Life Insurance Company now owns 229,607 shares of the company’s stock valued at $11,007,000 after buying an additional 42,361 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: The U.S. FDA approved Novo Nordisk’s Awiqli as a once-weekly basal insulin for children aged 10 and older with type 2 diabetes. The less-frequent dosing option could improve convenience and expand the product’s commercial opportunity. Novo Nordisk Wins FDA Nod For Weekly Insulin In Children With Type 2 Diabetes
Positive Sentiment: Oddo BHF raised its price target for Novo Nordisk from DKK 221 to DKK 305, signaling improved confidence in the company’s outlook. Oddo BHF Raises Target for Novo Nordisk Stock
Positive Sentiment: Novo Nordisk continues executing a share-repurchase program of up to DKK 15 billion. Buybacks can support earnings per share and provide demand for the stock. Novo Nordisk Share Repurchase Programme
Positive Sentiment: Erste Group Bank modestly increased its FY2026 and FY2027 EPS forecasts to $3.30 and $3.27, respectively, although both remain below the broader $3.42 consensus estimate.
Neutral Sentiment: Healthcare stocks weakened broadly in late trading, indicating that part of Novo Nordisk’s recent pressure may reflect sector-wide risk aversion rather than company-specific news. Sector Update: Healthcare Stocks Decline Late Afternoon
Negative Sentiment: A U.S. judge refused Novo Nordisk’s request to block Eli Lilly’s Zepbound advertising. The ruling allows a major obesity-drug rival to continue comparative marketing, potentially intensifying competition and limiting Novo’s ability to challenge Lilly’s messaging. Novo Nordisk Denied Injunction Against Eli Lilly’s Advertising

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.